Five-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation: results from the Tendyne Expanded Clinical Study
ESC Heart Failure · 04.07.2026 · 13 (4)
DOI: 10.1093/eschf/xvag175 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, online erschienen am 27.06.2026. Verfasst von David W M Muller und 27 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, St.Vincent's Hospital Sydney, Victoria Street, Darlinghurst, NSW 2010, Australia. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Transcatheter Mitral Valve Replacement, Mitral Valve, Heart Valve Prosthesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott.
Abstract (Originalsprache)
Aims
Transcatheter mitral valve replacement (TMVR) with the Tendyne Mitral Valve System is a treatment option for patients with severe symptomatic mitral regurgitation (MR) unsuitable for conventional mitral valve surgery or transcatheter edge-to-edge repair (TEER). This study sought to evaluate the safety and effectiveness of TMVR through 5-year follow-up. Methods and Results The Tendyne Expanded Clinical Study is a prospective, single-arm, multicentre study that enrolled patients between November 2014 and June 2020. The study enrolled 191 patients (mean age 74.1 ± 8.0 years, 62.8% male, 70.2% New York Heart Association Class (NYHA) class III/IV, 88.5% secondary MR), of whom 186 (97.4%) underwent TMVR with Tendyne. MR grade decreased from ≥3+ in 99.5% patients at baseline to grade ≤1+ in 95.3% at 5 years. In those patients surviving to 5 years (n = 49), durable symptomatic improvement was evidenced by 73.5% patients being in NYHA class I/II at 5 years. The Kansas City Cardiomyopathy Questionnaire overall summary score increased from 48.5 ± 22.5 points at baseline to 67.6 ± 21.5 points at 5 years. Serious adverse events that occurred through 5 years included life-threatening bleeding (11.5%), fatal bleeding (2.6%), renal insufficiency/failure (28.8%), endocarditis (7.3%), device thrombosis (5.8%), and new onset atrial fibrillation (13.1%). No structural device degeneration or device embolism occurred through 5 years.
Conclusions
The Tendyne TMVR was effective at achieving immediate and sustainable elimination of MR, which was associated with symptomatic improvement and absence of structural valve degeneration in a high-risk cohort over 5 years. These findings support TMVR with the Tendyne System as an alternative for patients with appropriate mitral valve anatomy and symptomatic secondary MR unsuitable for mitral surgery or TEER.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, St.Vincent's Hospital Sydney, Victoria Street, Darlinghurst, NSW 2010, Australia.
- Cardiology Department, Royal Brompton Hospital, London, UK.
- Banner Heart Institute, Banner University Medical Center, Phoenix, AZ, USA.
- Department of Internal Medicine, Abbott Northwestern Hospital, Minneapolis, MN, USA.
- Department of Cardiothoracic and Vascular Surgery, Oslo University Hospital, Oslo, Norway.
- Department of Medicine, Emory University Hospital, Atlanta, GA, USA.
ORCID-Profile: David W M Muller, Vinay Badhwar, Erwan Donal, Thomas Modine
Förderung
- Abbott
Zitieren
APA
Muller, D. W. M., Duncan, A., Sorajja, P., Dahle, G., Babaliaros, V., Lubos, E., Badhwar, V., Denti, P., Eng, M. H., Grayburn, P., Bethea, B., Walters, D., Nickenig, G., Petronio, A. S., Donal, E., Thourani, V. H., Mumtaz, M., Modine, T., Dumonteil, N., …, & Conradi, L. (2026). Five-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation: results from the Tendyne Expanded Clinical Study. ESC Heart Failure, 13(4). https://doi.org/10.1093/eschf/xvag175
Vancouver
Muller DWM, Duncan A, Sorajja P, Dahle G, Babaliaros V, Lubos E, et al. Five-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation: results from the Tendyne Expanded Clinical Study. ESC Heart Failure. 2026;13(4). doi:10.1093/eschf/xvag175
BibTeX
@article{Muller2026,
author = {Muller, David W M and Duncan, Alison and Sorajja, Paul and Dahle, Gry and Babaliaros, Vasilis and Lubos, Edith and Badhwar, Vinay and Denti, Paolo and Eng, Marvin H and Grayburn, Paul and Bethea, Brian and Walters, Darren and Nickenig, Georg and Petronio, Anna Sonia and Donal, Erwan and Thourani, Vinod H and Mumtaz, Mubashir and Modine, Thomas and Dumonteil, Nicolas and Obadia, Jean-Francois and Kapadia, Samir R and Guerrero, Mayra E and De Medeiros, Ricardo and McNutt, Robert and Nie, Hong and Chuang, Michael and Blanke, Philipp and Conradi, Lenard},
title = {Five-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation: results from the Tendyne Expanded Clinical Study},
journal = {ESC Heart Failure},
year = {2026},
volume = {13},
number = {4},
doi = {10.1093/eschf/xvag175}
}
EUVIMED